Inside Cover: A Reversible and Selective Inhibitor of Monoacylglycerol Lipase Ameliorates Multiple Sclerosis (Angew. Chem. Int. Ed. 50/2014) | Zendy

HernándezTorres Gloria | Zendy; Cipriano Mariateresa | Zendy; Hedén Erika | Zendy; Björklund Emmelie | Zendy; Canales Ángeles | Zendy; Zian Debora | Zendy; Feliú Ana | Zendy; Mecha Miriam | Zendy; Guaza Carmen | Zendy; Fowler Christopher J. | Zendy; OrtegaGutiérrez Silvia | Zendy; LópezRodríguez María L. | Zendy

Premium

Inside Cover: A Reversible and Selective Inhibitor of Monoacylglycerol Lipase Ameliorates Multiple Sclerosis (Angew. Chem. Int. Ed. 50/2014)

Author(s) -

HernándezTorres Gloria,

Cipriano Mariateresa,

Hedén Erika,

Björklund Emmelie,

Canales Ángeles,

Zian Debora,

Feliú Ana,

Mecha Miriam,

Guaza Carmen,

Fowler Christopher J.,

OrtegaGutiérrez Silvia,

LópezRodríguez María L.

Publication year - 2014

Publication title -

angewandte chemie international edition

Language(s) - English

Resource type - Reports

SCImago Journal Rank - 5.831

H-Index - 550

eISSN - 1521-3773

pISSN - 1433-7851

DOI - 10.1002/anie.201410020

Subject(s) - monoacylglycerol lipase , endocannabinoid system , diacylglycerol lipase , lipase , chemistry , int , pharmacology , multiple sclerosis , enzyme , biochemistry , medicine , computer science , immunology , receptor , operating system

The inhibition of monoacylglycerol lipase (MAGL) the enzyme responsible for the inactivation of the endocannabinoid 2‐arachidonoylglycerol, is a strategy for the treatment of multiple sclerosis. In their Communication on page 13765 ff., M. L. López‐Rodríguez and co‐workers describe a potent, reversible, and selective inhibitor of MAGL that slows the clinical progression of multiple sclerosis without inducing undesirable CB 1 ‐mediated side effect.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research